Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Biopharmx Corp (BPMX) Share Price
News articles about Biopharmx Corp (NYSE:BPMX) have trended somewhat positive recently, according to Accern. Accern scores the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Biopharmx Corp earned a coverage optimism score of 0.18 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 45.6848965790893 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Biopharmx Corp (NYSE:BPMX) traded up 0.9586% during mid-day trading on Friday, hitting $0.2949. The company had a trading volume of 1,235,160 shares. The firm’s market cap is $23.49 million. The stock’s 50 day moving average price is $0.30 and its 200 day moving average price is $0.46. Biopharmx Corp has a 52-week low of $0.19 and a 52-week high of $0.90.
Biopharmx Corp Company Profile
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
Receive News & Stock Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related stocks with our FREE daily email newsletter.